Clinical cases of treatment of hepatocellular carcinoma


Cite item

Full Text

Abstract

The article presents the clinical cases of sorafenib treatment of hepatocellular carcinoma. The experience of the Russian oncologistsdoes not only confirm the results of the international clinical research, but also demonstrates the possibility of prolonged administration of the drug for more than 3-4 years against a backdrop of high efficiency and controlled security profile.

About the authors

S A Lazarev

КГБУЗ Алтайский краевой онкологический диспансер; Алтайский филиал ФГБУ РОНЦ им. Н.Н.Блохина РАМН

K G Mamontov

КГБУЗ Алтайский краевой онкологический диспансер; Алтайский филиал ФГБУ РОНЦ им. Н.Н.Блохина РАМН

G M Manihas

СПб ГБУЗ Городской клинический онкологический диспансер

N Yu Antimonik

СПб ГБУЗ Городской клинический онкологический диспансер

References

  1. Практические рекомендации по лекарственному лечению больных первичным раком печени общества онкологов - химиотерапевтов (RUSSCO). Версия 2013; с. 229-36.
  2. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
  3. Bruix J, Raoul J.L, Sherman M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57 (4): 821-9;
  4. Llovet J.M, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90.
  5. Marrero J et al. Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) in >3000 sorafenib - treated patients: clinical findings in patients with liver dysfunction. Poster presented at the Annual Meeting of the American Society of Clinical Oncology, May 31 - June 4, 2013; Chicago, Illinois USA.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies